Focus on HIV Care

Back to articles

CMV Portends Poor Prognosis in HIV, but Vaccine in Development

KEY POINT

Patients with HIV-1 infection progress to AIDS-defining diseases more quickly when they are seropositive for cytomegalovirus (CMV), according to a recently published study. Several CMV vaccine candidates are in development, but authors of a review article argue that these are unlikely to be tested and brought to market without support by government agencies.

SOURCES

Arvin AM et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004;39:233–9.

Deayton JR et al. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet. 2004;363:2116–21.

Whitley RJ. Cytomegalovirus and HIV: inextricably entwined pathogens [editorial]. Lancet. 2004;363:2101–2.